LYEL Stock Analysis: Buy, Sell, or Hold?
LYEL - Lyell Immunopharma, Inc. Common Stock
$12.57
-2.32 (-15.58%)
▼
5d:
-24.87%
30d:
-39.33%
90d:
-47.18%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 14, 2026
Get Alerted When LYEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: LYEL is down 24.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: LYEL is down 24.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: LYEL is currently trading at $12.57, which is considered oversold relative to its 30-day fair value range of $16.22 to $20.66.
Technical Outlook: Technically, LYEL is in a downtrend. The price is currently testing key support at $12.34. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 15.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (98th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $42.20 (+235.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LYEL is in a downtrend. The price is currently testing key support at $12.34. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 15.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (98th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $42.20 (+235.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$16.22 -
$20.66
Company Quality Score
42/100
(HOLD)
Options IV Signal
98th percentile
(ELEVATED)
Volume Confirmation
HIGH
Confidence Score
61.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 98th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-15.6%)
- BULLISH: Trading 235.7% below Wall St target ($42.20)
- WARNING: Recommendation downgraded due to -24.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$16.22 -
$20.66
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$3.46
(27.5%)
Support & Resistance Levels
Support Level
$12.34
Resistance Level
$17.69
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.49
Wall Street Target
$42.20
(+235.7%)
Revenue Growth (YoY)
-71.4%
Share & Embed Analysis
Last updated: June 03, 2026 10:27 PM ET
Data refreshes hourly during market hours. Next update: 11:27 PM
Data refreshes hourly during market hours. Next update: 11:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LYEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Lynn Seely
SELL
7455 shares
2026-02-11
Stephen J Hill
SELL
1236 shares
2026-02-11
Gary K Lee
SELL
1671 shares
2026-02-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 58 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$548 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 55 HOLD |
